Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.88 -0.5%	$3.37	$1.07 ▼ $4.08	$1.02B	0.88	3.15 million shs	1.87 million shs
AMPH Amphastar Pharmaceuticals	$21.70 +2.0%	$24.35	$21.09 ▼ $53.96	$1.02B	0.72	499,122 shs	407,650 shs
PRQR ProQR Therapeutics	$2.40 +2.1%	$1.91	$1.07 ▼ $4.62	$252.50M	0.36	659,007 shs	161,703 shs
RCUS Arcus Biosciences	$9.44 +2.0%	$8.93	$6.50 ▼ $18.98	$999.81M	0.8	885,922 shs	948,509 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+0.52%	-2.26%	+8.94%	+89.32%	+174.65%
AMPH Amphastar Pharmaceuticals	+0.42%	-5.21%	-18.13%	-8.91%	-46.34%
PRQR ProQR Therapeutics	-0.42%	+2.17%	+23.68%	+106.14%	+25.00%
RCUS Arcus Biosciences	+2.56%	-0.53%	+1.97%	+17.45%	-41.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.7103 of 5 stars	3.6	1.0	4.0	2.2	0.8	0.6
AMPH Amphastar Pharmaceuticals	4.3176 of 5 stars	3.1	2.0	3.7	1.9	4.2	1.3
PRQR ProQR Therapeutics	2.5868 of 5 stars	3.6	5.0	0.0	2.7	0.0	0.0
RCUS Arcus Biosciences	2.3339 of 5 stars	4.4	1.0	0.0	1.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	73.97% Upside
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	49.00% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	233.33% Upside
RCUS Arcus Biosciences	2.89	Moderate Buy	$21.29	125.44% Upside

Current Analyst Ratings Breakdown

Latest PRQR, AKBA, AMPH, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	6.36	N/A	N/A	($0.23) per share	-16.87
AMPH Amphastar Pharmaceuticals	$731.97M	1.40	$5.13 per share	4.23	$15.23 per share	1.42
PRQR ProQR Therapeutics	$20.46M	12.34	N/A	N/A	$0.91 per share	2.64
RCUS Arcus Biosciences	$258M	3.88	N/A	N/A	$5.30 per share	1.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	7.86	6.60	5.52	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)

Latest PRQR, AKBA, AMPH, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AKBA Akebia Therapeutics	-$0.02	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	RCUS Arcus Biosciences	-$1.14	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	AMPH Amphastar Pharmaceuticals	$0.71	N/A	N/A	N/A	$173.42 million	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
PRQR ProQR Therapeutics	N/A	4.10	4.10
RCUS Arcus Biosciences	0.09	5.37	5.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
AMPH Amphastar Pharmaceuticals	65.09%
PRQR ProQR Therapeutics	32.65%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
AMPH Amphastar Pharmaceuticals	27.50%
PRQR ProQR Therapeutics	8.40%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.18 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable

PRQR, AKBA, AMPH, and RCUS Headlines

Recent News About These Companies

Arcus Biosciences (NYSE:RCUS) Shares Down 4.6% - Here's What Happened

July 15 at 2:44 PM | marketbeat.com

Arcus Biosciences’ quemliclustat receives US FDA orphan drug designation to treat pancreatic cancer

July 15 at 10:59 AM | pharmabiz.comP

Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For ... - Nasdaq

July 12, 2025 | nasdaq.com

Arcus Biosciences’ cancer drug gets orphan drug status

July 11, 2025 | msn.com

Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances

July 11, 2025 | appliedclinicaltrialsonline.comA

Arcus’ Quemliclustat Receives Orphan Drug Designation

July 11, 2025 | contractpharma.comC

Arcus Biosciences' Pancreatic Cancer Treatment Gets Orphan Drug Status

July 11, 2025 | marketwatch.com

Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

July 11, 2025 | finance.yahoo.com

Arcus Biosciences (NYSE:RCUS) Shares Gap Up - Here's Why

July 10, 2025 | marketbeat.com

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

July 10, 2025 | gurufocus.com

Arcus Biosciences (NYSE:RCUS) Stock Price Up 8.1% - Should You Buy?

July 9, 2025 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

July 9, 2025 | businesswire.com

Arcus Biosciences (NYSE:RCUS) Trading Down 2.9% - Here's What Happened

July 3, 2025 | marketbeat.com

Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment

July 1, 2025 | msn.com

Arcus Biosciences (NYSE:RCUS) Trading Down 6.3% - Here's What Happened

June 27, 2025 | marketbeat.com

Incyte, FDA, Sun Pharma and more—Chutes & Ladders

June 27, 2025 | fiercebiotech.comF

Arcus Biosciences Announces New Employment Inducement Grants - Business Wire

June 26, 2025 | businesswire.com

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

June 26, 2025 | msn.com

Precision BioSciences Shares Surge Following FDA Rare Pediatric Disease Designation

June 25, 2025 | msn.com

Precision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%

June 25, 2025 | msn.com

Arcus Biosciences, Inc. (RCUS) Cash Flow - Yahoo Finance

June 24, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR, AKBA, AMPH, and RCUS Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.88 -0.02 (-0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$3.88 0.00 (-0.13%)

As of 06:51 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Amphastar Pharmaceuticals NASDAQ:AMPH

$21.70 +0.43 (+2.02%)

Closing price 04:00 PM Eastern

Extended Trading

$21.75 +0.05 (+0.23%)

As of 04:20 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

ProQR Therapeutics NASDAQ:PRQR

$2.40 +0.05 (+2.13%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 -0.15 (-6.04%)

As of 06:18 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Arcus Biosciences NYSE:RCUS

$9.44 +0.18 (+1.97%)

Closing price 03:59 PM Eastern

Extended Trading

$9.42 -0.02 (-0.23%)

As of 06:29 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time